Health Care Antitrust Weekly: TCF Launches Monthly Litigation and Investigations Tracker; Judge Rules in Teva Patent Case; Corcept at Risk of Losing Market Share, Per 2025 Formulary Design Changes
The Federal Trade Commission publishes second report on PBMs, focusing on how the Big Three PBMs markup specialty generic drug prices. The PBMs enjoyed excess revenues of $7.3 billion, the FTC wrote in its report, comparing revenues to the National Average Drug Acquisition Cost (NADAC),...